Van ECK Associates Corp grew its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 5,269.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 83,010 shares of the company's stock after purchasing an additional 81,464 shares during the period. Van ECK Associates Corp owned approximately 0.10% of CRISPR Therapeutics worth $3,267,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also recently made changes to their positions in the company. Highline Wealth Partners LLC acquired a new position in shares of CRISPR Therapeutics during the fourth quarter valued at about $39,000. Western Pacific Wealth Management LP raised its holdings in shares of CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock worth $39,000 after acquiring an additional 500 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of CRISPR Therapeutics in the 3rd quarter worth about $40,000. Darwin Wealth Management LLC acquired a new stake in shares of CRISPR Therapeutics in the 3rd quarter worth about $43,000. Finally, Eastern Bank acquired a new stake in shares of CRISPR Therapeutics in the 3rd quarter worth about $70,000. Institutional investors and hedge funds own 69.20% of the company's stock.
CRISPR Therapeutics Stock Performance
Shares of CRSP traded down $2.52 during mid-day trading on Friday, hitting $47.91. 2,671,174 shares of the company traded hands, compared to its average volume of 2,550,435. The stock has a 50-day moving average price of $42.25 and a two-hundred day moving average price of $46.04. CRISPR Therapeutics AG has a 1 year low of $36.52 and a 1 year high of $91.10. The stock has a market cap of $4.11 billion, a price-to-earnings ratio of -10.96 and a beta of 1.67.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. On average, analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current year.
Wall Street Analyst Weigh In
Several equities research analysts have commented on CRSP shares. Needham & Company LLC reiterated a "buy" rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, February 12th. The Goldman Sachs Group reduced their target price on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a "neutral" rating for the company in a research report on Thursday, February 13th. Cantor Fitzgerald reissued a "neutral" rating on shares of CRISPR Therapeutics in a research report on Wednesday. Truist Financial increased their target price on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the company a "buy" rating in a research report on Wednesday, February 12th. Finally, Evercore ISI raised shares of CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and increased their target price for the company from $60.00 to $99.00 in a research report on Friday, February 14th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $74.40.
Get Our Latest Stock Analysis on CRSP
Insider Activity
In other news, CEO Samarth Kulkarni sold 18,360 shares of the business's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the transaction, the chief executive officer now directly owns 171,613 shares of the company's stock, valued at $9,473,037.60. The trade was a 9.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.10% of the stock is owned by corporate insiders.
CRISPR Therapeutics Company Profile
(
Free Report)
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Featured Articles
Before you consider CRISPR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.
While CRISPR Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
